Hologic And Biotheranostics To Present New Data At ASCO 2025 Highlighting Breast Cancer Index Test's Impact In Guiding Extended Endocrine Therapy Decisions For Over 2,800 HR+ Breast Cancer Patients

Benzinga · 05/22 21:28

Completed assessment of more than 2,800 patients highlights the profound impact of the test in helping to predict the likelihood of extended endocrine therapy benefit for patients with HR+ breast cancer to support more informed care decisions

Hologic, Inc. (NASDAQ:HOLX) and its subsidiary, Biotheranostics, Inc., today announced new data demonstrating the significant clinical impact of the Breast Cancer Index® (BCI®) test, which will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting on June 2, 2025.